Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
22 11월 2024 - 10:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of November 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
EXHIBIT INDEX
|
Exhibit No.
|
Description of Exhibit
|
|
99.1
|
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: November 22, 2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
Indivior To Participate in Upcoming Investor Event
Slough, UK, and Richmond, VA, November 22, 2024 – Indivior PLC (NASDAQ/LSE: INDV) today announced
that it will participate in the following investor
event:
●
Piper Sandler 36th
Annual Healthcare Conference –
New York City, NY
Mark Crossley, Chief Executive Officer, and Ryan
Preblick, Chief Financial Officer, will host 1x1 / group meetings
on Tuesday, December 3rd.
Mark Crossley will also participate in a fireside discussion on
Tuesday, December 3rd
at 10:00 a.m. US ET. Interested
investors should contact their Piper Sandler representative to
schedule a meeting. The fireside chat will be publicly available
and can be viewed using the following weblink:
https://event.webcasts.com/starthere.jsp?ei=1697247&tp_key=c34d7b2697
About Indivior
Indivior
is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders
(SUD), overdose and serious mental illnesses. Our vision is that
all patients around the world will have access to evidence-based
treatment for the chronic conditions and co-occurring disorders of
SUD. Indivior is dedicated to transforming SUD from a global human
crisis to a recognized and treated chronic disease. Building on its
global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this
category and potentially address other chronic conditions and
co-occurring disorders of SUD. Headquartered in the United States
in Richmond, VA, Indivior employs over 1,000 individuals globally
and its portfolio of products is available in over 30 countries
worldwide. Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by visiting
www.linkedin.com/company/indivior.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or
jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
Tel: 804-263-3978 or timothy.owens@indivior.com
###
Indivior (NASDAQ:INDV)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Indivior (NASDAQ:INDV)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
